等待开盘 12-15 09:30:00 美东时间
0.000
0.00%
Ovid Therapeutics任命Petra Kaufmann博士为首席医疗官,负责领导临床、医学和监管战略。Kaufmann博士拥有丰富的CNS药物开发经验,曾在Vigil Neuroscience、Affinia Therapeutics和Novartis Gene Therapies担任重要职位,并在NIH推动罕见病研究。她的加入将加强Ovid的研发能力,推动其GABA-AT抑制剂OV329和KCC2激活剂的开发。Kaufmann博士表示,期待与Ovid团队合作,为患者带来创新疗法。
12-02 12:00
Liz Ann Sonders, the Chief Investment Strategist at Charles Schwab & Co. (NYSE: SCHW) highlighted certain unusual divergences in the small cap markets.
10-10 16:27
Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.42) by 32.08 percent. This is a 7.69 percent decrease over losses of $(0.52) per share
08-05 21:37
An update from Vigil Neuroscience Inc ( ($VIGL) ) is now available. On August 4...
08-05 21:28
Vigil Neuroscience Inc ( ($VIGL) ) has issued an update. On May 21, 2025, Vigil...
07-28 19:57
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
07-25 21:27
Vigil Neuroscience Inc ( ($VIGL) ) has shared an announcement. On May 21, 2025,...
07-17 19:27
NEW YORK, July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
07-04 05:34
New activity is brewing for Vigil Neuroscience Inc ( ($VIGL) ). The company has...
06-30 23:56
InMed stock jumped after preclinical data showed INM-901 lowered brain inflammation tied to Alzheimer's and improved cognitive function in models.
06-24 21:01